China boasts 48% price cut on insulin as domestic drugmakers eclipse Big Pharma in bulk order
In a first, China has featured insulin in its centralized drug procurement program — but the bulk order comes at a sizable cost for multinational pharma players.
Novo Nordisk, Sanofi and Eli Lilly were among eight companies, domestic and foreign, whose insulin products won tenders from the Chinese public hospital system. In exchange, the drugs’ prices were cut, on average, by 48%, saving the medical institutions a collective $1.4 billion on the first batch of 210 million doses, according to state media.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
